Adjuvant treatments for resectable pancreatic cancer
Adjuvant treatments for resectable pancreatic cancer
复制标题
DOI：
10.1007/s00534-008-1357-3
复制
发表时间：
2008-09-01
期刊：
影响因子：
--
通讯作者：
Kosuge, Tomoo
中科院分区：
文献类型：
--
作者：
Ueno, Hideki;Kosuge, Tomoo
胰腺癌仍然是最难成功治疗的恶性肿瘤之一。大多数患者患有无法切除的晚期癌症，只有20%的患者可以接受切除术。即使手术切除，复发率也很高，术后生存率也很差。因此，需要有效的辅助治疗来改善胰腺癌患者的预后。到目前为止，对于这种疾病还没有普遍接受的标准辅助治疗：放化疗后化疗在美国被认为是最佳治疗方法，而单纯化疗是欧洲目前的标准。然而，最近的随机对照试验（RTOG [放射治疗肿瘤学组] 9704；CONKO [Charite Onkologie]-001；以及一项日本研究）表明吉西他滨辅助化疗对可切除胰腺癌患者有好处。本文将回顾该疾病辅助治疗的临床试验，包括最近的试验结果。
Pancreatic cancer remains one of the most challenging malignancies to treat successfully. The majority of patients present with unresectable advanced-stage cancer, and only 20% of patients can undergo resection. Even if surgical resection is performed, the recurrence rate is high and the survival rate after surgery is poor. Therefore, effective adjuvant therapy is needed to improve the prognosis of patients with pancreatic cancer. Until now, no universally accepted standard adjuvant therapy for this disease has been available: chemoradiotherapy followed by chemotherapy is considered the optimal therapy in the United States, while chemotherapy alone is the current standard in Europe. However, recent randomized controlled trials (RTOG [Radiation Therapy Oncology Group] 9704; CONKO [Charite Onkologie]-001; and a Japanese study) have suggested a benefit of adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer. This article will review the clinical trials of adjuvant therapy for this disease, including the results of recent trials.